Results 81 to 90 of about 1,702,455 (203)

Overall Survival Benefit and Long‐Term Safety of Romiplostim in Persistent Chemotherapy‐Induced Thrombocytopenia

American Journal of Hematology, Volume 101, Issue 12, Page 2957-2960, December 2026.
Andrew B. Song, Gerald A. Soff
wiley   +1 more source

Evaluating the Efficacy of Cytokine‐Directed Therapies in the Management of VEXAS Syndrome

ACR Open Rheumatology, Volume 8, Issue 10, October 2026.
Objective To evaluate the efficacy of cytokine‐directed therapies in VEXAS (vacuoles, E1 enzyme, X‐linked, autoinflammatory somatic) syndrome using previously proposed treatment response criteria. Methods All patients with genetically confirmed VEXAS syndrome who received targeted therapies with JAK inhibitors (JAKi), tumor necrosis factor α inhibitors
Daniel Montes, Hannah E. Langenfeld, Andrew C. Hanson, Cynthia S. Crowson, Mrinal M. Patnaik, Ronald S. Go, Kambiz Kalantari, Yael Kusne, Terra Lasho, Abhishek A. Mangaonkar, Horatiu Olteanu, Kaaren K. Reichard, Megan M. Sullivan, David S. Viswanatha, Kenneth J. Warrington, Matthew J. Koster   +15 more
wiley   +1 more source

Eltrombopag: an update on the novel, non-peptide thrombopoietin receptor agonist for the treatment of immune thrombocytopenia.

, 2010
Immune thrombocytopenia (ITP) is characterised by a transient or persistent decrease in platelets accompanied by an increased risk of bleeding, which can have a significant negative impact on patients' health-related quality of life.
Imbach P, Kühne T
core   +1 more source

Case Report: Dangerous liaisons between splenectomy and eltrombopag-induced chronic thromboembolic pulmonary hypertension in patients with immune thrombocytopenia: report of two cases and review of the literature

Frontiers in Cardiovascular Medicine
IntroductionPrimary immune thrombocytopenia is an autoimmune bleeding disorder characterized by variable immune-mediated platelet destruction. These patients have reported thrombotic complications, both venous and arterial, in addition to bleeding ...
Roberto Castelli, Enrico Atzori, Alessandro Palmerio Delitala, Salvatore Antonio Masala, Valentina Micheluzzi, Enrico Ponti, Enrico Ponti, Giuseppe Sanna, Dante Castro, Antonio Gidaro, Mattia Donadoni, Roberto Manetti, Pierluigi Merella, Nicia Isabella Profili, Andrea Maria D'Armini, Gavino Casu, Gavino Casu   +16 more
doaj   +1 more source

Recombinant Human Thrombopoietin Reduces the Need for Platelet Transfusion in Patients With Chronic Liver Disease and Thrombocytopenia

American Journal of Hematology, Volume 101, Issue 10, Page 2571-2580, October 2026.
ABSTRACT Chronic liver disease (CLD)‐related thrombocytopenia can limit the feasibility of invasive procedures. Recombinant human thrombopoietin (rhTPO) has demonstrated a favorable safety profile without hepatotoxicity. We evaluated the efficacy and safety of rhTPO in patients with CLD‐related thrombocytopenia who were undergoing elective invasive ...
Yifan Han, Ning Lin, Jinghang Xu, Sikui Wang, Jinglan Jin, Jia Shang, Yongning Xin, Youwen Tan, Dazhi Zhang, Jinlin Hou, Ping An, Wen Xie, Yujuan Guan, Qingfang Xiong, Hong Wu, Huiguo Ding, Yu Chen, Rongkuan Li, Zhili Wen, Mingqin Lu, Jinhui Yang, Zhongyin Zhou, Yongjian Zhou, Zujiang Yu, Kecan Lin, Wei Wang, Yan Huang, Yuemin Nan, Xinhua Luo, Rongshu Shi, Yi Kang, Tao Han, Shiyan Chen, Kai Wang, Yunfeng Shan, Jiaping Li, Pingguo Liu, Zheng Lu, Jun Chen, Zhen Liu, Liaoyun Zhang, Li Yang, Jifang Sheng, Zhan Zeng, Yanyan Yu, Xiaoyuan Xu   +45 more
wiley   +1 more source

Thrombopoietin receptor agonist romiplostim in refractory thrombocytopenia as a bridging therapy to the second allogeneic stem cell transplantation [PDF]

, 2019
Thrombopoietin (TPO) receptor agonist romiplostim mimic the action of TPO and stimulate the activation, proliferation and maturation of megakaryocytes, resulting in an increase in circulating platelet counts.
Kilić, Paula, Pulanić, Dražen
core   +1 more source

Eltrombopag Added to Standard Immunosuppressive Treatment as Front‐Line Therapy for Severe Aplastic Anemia: Long‐Term Outcomes of the Phase‐3 Randomized Superiority EBMT‐SAAWP RACE Study

American Journal of Hematology, Volume 101, Issue 10, Page 2520-2532, October 2026.
ABSTRACT The RACE study (NCT02009747) compared horse antithymocyte globulin (hATG) plus cyclosporine A (CsA) ± eltrombopag as initial immunosuppressive treatment (IST) for severe aplastic anemia. Here we report the final 2‐year analysis of this prospective randomized phase III study.
Antonio M. Risitano, Simona Iacobelli, Austin Kulasekararaj, Marleen van Os, Sofie R. Terwel, Joe Tuffnell, Brian Piepenbroek, Morag Griffin, Constantijn J. M. Halkes, Christian Recher, Fiorenza Barraco, Edouard Forcade, Juan Carlos Vallejo, Beatrice Drexler, Jean‐Baptiste Mear, Roochi Trikha, Shreyans Gandhi, Anna Maria Raiola, L. G. M. Daenen, Marco R. de Groot, Etienne Daguindau, Erfan Nur, Wilma Barcellini, Nigel H. Russell, Louis Terriou, Anna Paola Iori, Walter Barberi, Anna Sureda, Isabel Sánchez‐Ortega, Blanca Xicoy, Isidro Jarque, James Cavenagh, Flore Sicre de Fontbrune, Camilla Frieri, Talha Munir, Jennifer M. L. Tjon, Suzanne Tavitian, Aline Praire, Laurence Clement, Florence Rabian, Luana Marano, Anita Hill, Elena Palmisani, Petra Muus, Serena Marotta, Fabiana Cacace, Marica Laurino, Jakob R. Passweg, Gérard Socié, Ghulam J. Mufti, Carlo Dufour, Régis Peffault de Latour, Severe Aplastic Anaemia Working Party of the EBMT   +52 more
wiley   +1 more source

Pharmacist intervention through protocol-based pharmacotherapy management is effective to ensure safety in invasive procedures for chronic liver disease

Journal of Pharmaceutical Health Care and Sciences
Background The risk of hemorrhagic complications in patients with chronic liver disease during invasive procedures should be considered. Patients with low platelet counts were administered platelet products prior to procedures based on a physician's ...
Yuuka Shibata, Yuki Koga, Yuki Sato, Emiko Mashida, Tomokazu Kawaoka, Eisuke Murakami, Kei Amioka, Yusuke Johira, Kensuke Naruto, Takanori Taogoshi, Tomoharu Yokooji, Masataka Tsuge, Hiroaki Matsuo   +12 more
doaj   +1 more source

THROMBOPOIETIN RECEPTOR FRAGMENTS AND USES THEREOF

, 2023
The present invention relates to a polypeptide comprising fragments of the extracellular domain of thrombopoietin receptor, a fusion protein and a pharmaceutical composition comprising said polypeptide, and uses ...
UNIVERSITE CATHOLIQUE DE LOUVAIN, Constantinescu, Stefan N., Nedelec, Audrey, Papadopoulos, Nicolas   +3 more
core  

The role of eltrombopag in the management of hepatitis C virus-related thrombocytopenia

Hepatic Medicine: Evidence and Research, 2013
Fazal-i-Akbar Danish,1 Saeeda Yasmin21James Paget University Hospital, Great Yarmouth, Norfolk, United Kingdom; 2Shifa International Hospital, Islamabad, PakistanAbstract: Eltrombopag is a 2nd generation thrombopoietin-receptor agonist. It binds with the
Danish FA, Yasmin S
doaj